share_log

Is Guangzhou Kingmed Diagnostics Group (SHSE:603882) Using Too Much Debt?

Is Guangzhou Kingmed Diagnostics Group (SHSE:603882) Using Too Much Debt?

金域醫學(SHSE:603882)是否使用了過多的債務?
Simply Wall St ·  08/26 22:34

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. Importantly, Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) does carry debt. But the more important question is: how much risk is that debt creating?

傳奇基金經理李露(由查理·芒格支持)曾經說過:「最大的投資風險不是價格的波動,而是你是否會遭受永久的資本損失。」因此,很明顯,當你考慮任何給定股票的風險時,你需要考慮債務,因爲過多的債務會使公司陷入困境。重要的是,廣州金邁診斷集團有限公司(上海證券交易所代碼:603882)確實有債務。但更重要的問題是:這筆債務會帶來多大的風險?

When Is Debt Dangerous?

債務何時危險?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. When we think about a company's use of debt, we first look at cash and debt together.

債務可以幫助企業,直到企業難以償還債務,無論是新資本還是自由現金流。如果情況變得非常糟糕,貸款人可以控制業務。但是,更常見(但仍然代價高昂)的情況是,公司必須以低廉的價格發行股票,永久稀釋股東,以支撐其資產負債表。話雖如此,最常見的情況是公司合理地管理其債務,並從自己的利益出發。當我們考慮公司使用債務時,我們首先要同時考慮現金和債務。

How Much Debt Does Guangzhou Kingmed Diagnostics Group Carry?

廣州金邁診斷集團揹負了多少債務?

You can click the graphic below for the historical numbers, but it shows that as of March 2024 Guangzhou Kingmed Diagnostics Group had CN¥444.5m of debt, an increase on CN¥380.4m, over one year. But it also has CN¥2.11b in cash to offset that, meaning it has CN¥1.66b net cash.

你可以點擊下圖查看歷史數字,但它顯示,截至2024年3月,廣州金邁診斷集團在一年多的時間裏有44450萬元人民幣的債務,比38040萬加元人民幣有所增加。但它也有21.1元人民幣的現金來抵消這一點,這意味着它的淨現金爲16.6元人民幣。

1724726093778
SHSE:603882 Debt to Equity History August 27th 2024
SHSE: 603882 債務與股權比率歷史記錄 2024 年 8 月 27 日

How Strong Is Guangzhou Kingmed Diagnostics Group's Balance Sheet?

廣州金邁診斷集團的資產負債表有多強?

According to the last reported balance sheet, Guangzhou Kingmed Diagnostics Group had liabilities of CN¥2.65b due within 12 months, and liabilities of CN¥566.8m due beyond 12 months. Offsetting these obligations, it had cash of CN¥2.11b as well as receivables valued at CN¥5.63b due within 12 months. So it actually has CN¥4.52b more liquid assets than total liabilities.

根據上次報告的資產負債表,廣州金邁診斷集團的負債爲26.5元人民幣,12個月後到期的負債爲56680萬元人民幣。除了這些債務外,它還有21.1元人民幣的現金以及價值56.3元人民幣的應收賬款將在12個月內到期。因此,它的流動資產實際上比總負債多45.2元人民幣。

This surplus strongly suggests that Guangzhou Kingmed Diagnostics Group has a rock-solid balance sheet (and the debt is of no concern whatsoever). Having regard to this fact, we think its balance sheet is as strong as an ox. Simply put, the fact that Guangzhou Kingmed Diagnostics Group has more cash than debt is arguably a good indication that it can manage its debt safely.

這種盈餘強烈表明廣州金邁診斷集團的資產負債表堅如磐石(債務根本不令人擔憂)。考慮到這一事實,我們認爲其資產負債表像牛一樣強勁。簡而言之,廣州金邁診斷集團的現金多於債務,這一事實可以說是一個很好的跡象,表明它可以安全地管理債務。

It is just as well that Guangzhou Kingmed Diagnostics Group's load is not too heavy, because its EBIT was down 91% over the last year. When it comes to paying off debt, falling earnings are no more useful than sugary sodas are for your health. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if Guangzhou Kingmed Diagnostics Group can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

同樣,廣州金邁診斷集團的負荷並不太重,因爲其息稅前利潤比去年下降了91%。在還清債務方面,收入下降對健康的作用並不比含糖的蘇打水更有用。在分析債務水平時,資產負債表是顯而易見的起點。但最終,該業務未來的盈利能力將決定廣州金邁診斷集團能否隨着時間的推移加強其資產負債表。因此,如果你想看看專業人士的想法,你可能會發現這份關於分析師利潤預測的免費報告很有趣。

Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. Guangzhou Kingmed Diagnostics Group may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Looking at the most recent three years, Guangzhou Kingmed Diagnostics Group recorded free cash flow of 44% of its EBIT, which is weaker than we'd expect. That's not great, when it comes to paying down debt.

最後,企業需要自由現金流來償還債務;會計利潤根本無法減少債務。廣州金邁診斷集團資產負債表上可能有淨現金,但研究該企業如何將其利息稅前收益(EBIT)轉換爲自由現金流仍然很有趣,因爲這將影響其對債務的需求和管理能力。從最近三年來看,廣州金邁診斷集團錄得的自由現金流佔其息稅前利潤的44%,低於我們的預期。在償還債務方面,這並不好。

Summing Up

總結

While it is always sensible to investigate a company's debt, in this case Guangzhou Kingmed Diagnostics Group has CN¥1.66b in net cash and a decent-looking balance sheet. So we are not troubled with Guangzhou Kingmed Diagnostics Group's debt use. The balance sheet is clearly the area to focus on when you are analysing debt. However, not all investment risk resides within the balance sheet - far from it. These risks can be hard to spot. Every company has them, and we've spotted 2 warning signs for Guangzhou Kingmed Diagnostics Group you should know about.

儘管調查公司的債務總是明智的,但在本案中,廣州金邁診斷集團的淨現金爲16.6元人民幣,資產負債表看起來不錯。因此,我們對廣州金邁診斷集團的債務使用並不感到困擾。資產負債表顯然是分析債務時需要關注的領域。但是,並非所有的投資風險都存在於資產負債表中,遠非如此。這些風險可能很難發現。每家公司都有它們,我們已經發現了兩個你應該知道的廣州金邁診斷集團的警告標誌。

At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.

歸根結底,通常最好將注意力集中在沒有淨負債的公司身上。您可以訪問我們的此類公司的特別名單(所有公司都有利潤增長記錄)。它是免費的。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論